Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,642,265
  • Shares Outstanding, K 66,223
  • Annual Sales, $ 44,670 K
  • Annual Income, $ -789,610 K
  • 60-Month Beta 2.20
  • Price/Sales 82.86
  • Price/Cash Flow N/A
  • Price/Book 1.85
Trade BLUE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -3.07
  • Number of Estimates 11
  • High Estimate -0.98
  • Low Estimate -3.81
  • Prior Year -3.73
  • Growth Rate Est. (year over year) +17.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.82 +2.83%
on 09/11/20
61.27 -11.35%
on 09/03/20
-2.44 (-4.29%)
since 08/28/20
3-Month
52.82 +2.83%
on 09/11/20
68.39 -20.58%
on 08/06/20
-6.73 (-11.02%)
since 06/30/20
52-Week
38.95 +39.45%
on 03/17/20
99.36 -45.34%
on 01/17/20
-37.51 (-40.85%)
since 09/30/19

Most Recent Stories

More News
bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET.

BLUE : 53.92 (-1.96%)
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

BMY : 59.88 (-0.03%)
EBS : 103.01 (-1.27%)
TECH : 246.24 (-0.21%)
BLUE : 53.92 (-1.96%)
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

BMY : 59.88 (-0.03%)
SGEN : 194.97 (+2.10%)
BLUE : 53.92 (-1.96%)
ARWR : 42.83 (-1.36%)
BPMC : 92.42 (+0.93%)
VCNX : 1.7600 (-2.76%)
bluebird bio's LentiGlobin(TM) for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin(TM) for SCD gene therapy (bb1111), was granted eligibility to the Priority...

BLUE : 53.92 (-1.96%)
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

-- Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma

BMY : 59.88 (-0.03%)
BLUE : 53.92 (-1.96%)
Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BLUE : 53.92 (-1.96%)
Global Viral Vector Manufacturing Market 2020-2025: Growing Adoption of Adenoviral Vectors, Lentiviral Vectors, as Well as Retroviral Vectors

, /PRNewswire/ -- The report has been added to offering.

MKKGY : 29.2100 (-0.65%)
SDMHF : 340.4500 (-4.68%)
EBS : 103.01 (-1.27%)
MRK : 82.37 (+0.57%)
BLUE : 53.92 (-1.96%)
bluebird bio Announces September Investor Events

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

MS : 48.12 (+1.86%)
BLUE : 53.92 (-1.96%)
bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D(TM)) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT

--31 out of 32 patients in ALD-102 had stable Neurologic Function Scores following treatment with eli-cel, including 24 patients with a score of zero as of the last available visit

BLUE : 53.92 (-1.96%)
Novel Cancer Treatments Arise as Scientists Search for Answers

, /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In particular, the top three diagnosed cancers accounted...

ANPC : 3.86 (-2.28%)
EXAS : 101.98 (-0.03%)
BIIB : 281.18 (-0.41%)
BLUE : 53.92 (-1.96%)
EXEL : 24.15 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 57.59
1st Resistance Point 56.30
Last Price 53.92
1st Support Level 54.31
2nd Support Level 53.61

See More

52-Week High 99.36
Fibonacci 61.8% 76.28
Fibonacci 50% 69.15
Fibonacci 38.2% 62.03
Last Price 53.92
52-Week Low 38.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar